Cresco Labs, a Chicago, IL-based maker of a full suite of pharmaceutical-grade medical cannabis products, securing $100m in Series D funding round.
The backers were not disclosed.
The company intends to use the funds to continue to expand its presence to produce and dispense their suite of medically-focused and adult-use cannabis products.
Led by CEO Charlie Bachtell, Cresco currently operates in six states via such brands as Cresco, Remedi, Reserve and Mindy’s Edibles, which provide a full suite of dosed products catering to all consumers, from the novice to connoisseur, from the medically-minded to the recreational user.
The company was founded after winning three merit-based cultivation licenses in the Illinois market. They have since been awarded vertically-integrated licenses in Pennsylvania and Ohio, in addition to acquiring cultivation and dispensary operations in Arizona, Nevada and California earlier this year.